P

Pharmathen

Develops generic drugs and delivery technologies

Head of HR Excellence

Full-TimeUpdated on 10/17/2026
No salary listed
Expert
Bachelor's, Master's
Marousi, Greece
Hybrid
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science degree in Business Administration, Human Resources, or a related field is required.
  • A master's degree in Human Resources, Business Administration, or a related field is required.
  • At least 10 years of human resources management experience, including recruitment, labor law, and employee relations.
  • Drive for results and transformational leadership.
  • Proven team leadership, business acumen, and organizational skills to influence and implement initiatives across a large organization.
  • Knowledge of employment law and regulations, human resources information systems, and human resources systems for talent, performance, learning, and metrics.
  • Demonstrated managerial ability in a complex environment.
Responsibilities
  • Execute human resources strategy and implement programs, processes, and tools that support business objectives through efficient human resources systems, processes, and policies.
  • Ensure activities integrate with organizational quality management, health and safety, legal stipulations, and duty-of-care requirements.
  • Drive change management practices to enable organizational effectiveness by developing strategies that foster employee engagement and commitment.
  • Strengthen the organization through talent management frameworks and activities aligned with reward and recognition policies; prepare and run talent forums with human resources business partners and talent advisors; cultivate employer branding; design employee career paths; and design the onboarding framework.
  • Manage operational key performance indicators and monitor human resources performance through dashboards.
  • Develop strategic workforce plans in partnership with business leadership and talent acquisition, and create insights for improvement through human resources key performance indicators and analytics.
  • Develop, review, and revise human resources policies to align with organizational culture and comply with applicable laws and regulations.
  • Direct, delegate, motivate, and develop staff to provide appropriate support and services to the department and other business departments.

About the company

Pharmathen develops generic medicines and advanced drug-delivery technologies from its Greece-based manufacturing sites, exporting to branded pharmaceutical companies and patients worldwide. Its products include long-acting injectables, sustained-release formulations, and ophthalmic drugs, built on a strategy of Life Cycle Management and new technology platforms. The company operates with full vertical integration, handling research, development, manufacturing, and export, under facilities approved by the US FDA and EU. This enables it to deliver high-quality generic solutions and optimized dosage forms at scale. Pharmathen differentiates itself through a focused emphasis on drug-delivery platforms, continuous pipeline development, and end-to-end control over development and manufacturing. Its goal is to provide high-quality, affordable medicines while expanding its capabilities in innovative generic products and advanced delivery technologies for global markets.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

N/A

Headquarters

Athens, Greece

Founded

1969

Get referred to Pharmathen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Neuraxpharm's December 2024 alliance creates Europe-wide commercialization for Pharmathen's LAI pipeline.
  • CBL Patras acquisition expands peptide capacity and adds an FDA-approved manufacturing base.
  • NTC bought Pharmathen's ophthalmology unit, proving monetizable assets despite operational turmoil.

What critics are saying

  • FDA issued a 2026 warning letter and import alert over sterile manufacturing failures.
  • Reuters reported August 2026 paliperidone shortages from Pharmathen disruptions, hitting schizophrenia patients across Europe.
  • Partners Group wrote Pharmathen equity to zero in June 2026, signaling debt-driven distress and possible restructuring.

What makes Pharmathen unique

  • Pharmathen pairs drug-delivery R&D with in-house manufacturing across Greece and Europe.
  • Its 2024 Neuraxpharm pact locked Pharmathen into psychiatry long-acting injectables globally.
  • CBL Patras added FDA-approved peptide manufacturing, strengthening complex sterile capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Training Programs

Growth & Insights and Company News

Headcount

6 month growth

12%

1 year growth

12%

2 year growth

12%
PR Newswire
Dec 10th, 2025
NTC acquires Pharmathen's ophthalmology business, reaching €100M revenue with Wise Equity backing

NTC, an Italian pharmaceutical company specialising in ophthalmology, has completed the acquisition of Pharmathen's ophthalmology business unit with support from its main shareholder Wise Equity. The deal adds a consolidated portfolio of glaucoma treatments to NTC's offerings. The acquisition brings NTC's revenue to approximately €100 million, with over 80% derived from ophthalmology. The company now reaches more than 100 countries through over 250 distribution partners and gains entry into the US market through its B2B model. The acquired glaucoma portfolio includes many preservative-free formulations and complements NTC's existing therapeutic areas covering antibiotic therapy, inflammation, allergies and dry eye. Globally, around 80 million people suffer from glaucoma, a number expected to reach 112 million by 2040. Wise Equity's Wisequity VI fund, launched in May 2023 with €400 million in commitments, supported the transaction.

World Pharmaceutical Frontiers
Dec 13th, 2024
Neuraxpharm and Pharmathen partner to develop LAI psychiatry therapies

Neuraxpharm and Pharmathen have signed a co-development agreement to develop long-acting injectable (LAI) therapies for the psychiatry sector.

PR Newswire
Dec 12th, 2024
Neuraxpharm And Pharmathen Enter Into Strategic Co-Development Agreement To Develop Long-Acting Injectable Therapies

New therapies will allow patients greater choice and flexibility in the control of CNS disorders. BARCELONA, Spain, DÜSSELDORF, Germany, and ATHENS, Greece, Dec. 12, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leaders in the development and supply of long-acting injectable (LAI) therapies, announce a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen's long-acting therapeutic technologies (LATT) program. Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm

Financial Times
Jun 30th, 2024
Swiss buyout firm Partners Group lands deal for stake in €900mn biotech firm

The buyout fund bought Greece-based generics manufacturer Pharmathen in 2021 for €1.6bn including debt and last year invested alongside GHO in drug manufacturing outsourcer Sterling Pharma Solutions.

Ropes & Gray
Nov 6th, 2023
Ropes & Gray Advises Pharmathen on Acquisition of CBL Patras

Ropes & Gray has advised Pharmathen, a leading European complex drug delivery and formulation developer, on its acquisition of CBL Patras, a leading vertically integrated and US-FDA approved peptide manufacturer and supplier in Europe.